Skip to main content
. 2015 Dec 21;7(4):4210–4225. doi: 10.18632/oncotarget.6704

Figure 6. The effects of shVDAC1 and compounds disrupting VDAC1 and hexokinase interactions on the cytotoxicity of cisplatin in SiHa and CaSki cervical cancer cells.

Figure 6

A. Two mM of methyl jasmonate significantly enhanced the cell toxicity of cisplatin at concentrations of 2.5, 5 and 10μM in the SiHa cervical cancer cells. B. Two mM methyl jasmonate enhanced the cell toxicity of cisplatin at concentrations of 0, 2.5, 5 and 10μM in the CaSki cervical cancer cells but without statistical significance. C. FiftyμM of clotrimazole significantly enhanced the cell toxicity of cisplatin at concentrations of 5 and 10μM in the SiHa cervical cancer cells. D. FiftyμM of clotrimazole significantly enhanced the cell toxicity of cisplatin at concentrations of 2.5, 5 and 10μM in the CaSki cervical cancer cells. E. Cell cytotoxicity was enhanced when the VDAC1 gene was silenced at concentrations of 1.25-20μM of cisplatin in the SiHa shVDAC1 #128 and #564 cancer cells. F. Cell cytotoxicity was enhanced when the VDAC1 gene was silenced at concentrations of 1.25-5μM of cisplatin in the CaSki shVDAC1 #128 and #564 cancer cells. The VDAC1 gene was silenced using lentiviruses carrying shVDAC1 #128 and #564 in SiHa and CaSki cervical cancer cells. VDAC1, voltage-dependent anion channel 1. *p<0.05.